TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects ...

Tonix Pharmaceuticals (TNXP) presented data in an oral presentation at the World Vaccine Congress Washington 2025, held April 21-24, 2025, in ...

Tonix Pharmaceuticals presented positive preclinical data for TNX-801, a single-dose vaccine against mpox and smallpox, at a recent conference. Tonix Pharmaceuticals has presented encouraging ...

The FDA has approved a new freeze-dried formulation of Jynneos (smallpox and mpox vaccine, live, non-replicating).

In observance of World Immunisation Week, WHO's Saima Wazed emphasizes the importance of vaccines in protecting global health ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

Most people in the U.S. have received vaccines to protect against infectious diseases. A vaccine against smallpox led to the ...

But in 1796, Edward Jenner created the smallpox vaccine — the first successful vaccine to be developed. Today, thanks to the power of that vaccine, investments, action, and advocacy, smallpox was ...

even at high doses “TNX-801 shows promise as a potential mpox and smallpox vaccine by providing protective immunity to animals with a single-dose,” said Seth Lederman, M.D., Chief Executive ...